pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,179 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1891Endpoints1465Fierce Biotech779BioSpace767BioPharma Dive555raps254onclive165fda recalls
therapy area
allOncology13095Rare Disease3387Immunology3069Cardiology2866Hematology2335Pulmonology2300Vaccines
  • RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer data
    RevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…
    BioSpace · 8h agoPositive readoutPositive↗ source
  • Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory market
    Analysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…
    BioSpace · 8h agoDealPositive
← prev
page 1 of 168
next →
125
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
↗ source
  • Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
    Merck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
    Fierce Biotech · 15h agoPositive readoutPositive↗ source
  • Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapy
    Compass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…
    BioPharma Dive · 3h agoRegulatoryNeutral↗ source
  • Erasca reports 44% response in KRAS-mutated pancreatic cancer, eyes Phase 3 trial
    Erasca announced that 44% of patients with KRAS-mutated pancreatic cancer showed a response to its experimental drug ERAS-0015 in a small Phase 1 study. The company said the treatment was well tole…
    BioPharma Dive · 6h agoPositive readoutNeutral↗ source
  • Merck-Kelun ADC sac-TMT shows overall survival benefit in Phase 3 stomach cancer trial
    Merck, licensing the TROP2-targeting antibody drug conjugate sac-TMT from Kelun-Biotech, reported that the therapy improved overall survival in patients with advanced gastroesophageal adenocarcinom…
    BioSpace · 9h agoPositive readoutPositive↗ source
  • China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slump
    Biotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
    BioPharma Dive · 11h agoDealNeutral↗ source
  • FDA delays decision on Savara's rare lung disease therapy, pushing back deadline
    The FDA announced it will not meet the Nov. 22 PDUFA date for Savara's biologics license application for its inhaled therapy molgramostim (Molbreevi) targeting autoimmune pulmonary alveolar protein…
    BioSpace · 7h agoRegulatoryNegative↗ source
  • Sanofi considers Insmed acquisition as FDA criticizes J&J bladder cancer drug claims; Japan eyes higher drug prices
    Sanofi is reportedly evaluating a possible takeover of Insmed, signaling continued consolidation activity in the biotech sector. The U.S. Food and Drug Administration has issued a warning to Johns…
    STAT · 9h agoDealNeutral↗ source
  • Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filing
    Celldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…
    BioPharma Dive · 10h agoNegative readoutNegative↗ source
  • FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are ranked
    The Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…
    STAT · 14h agoRegulatoryNeutral↗ source
  • FDA delays decision on Belite Bio's Stargardt disease drug to May 12
    The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
    Fierce Biotech · 14h agoRegulatoryNeutral↗ source
  • Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitis
    Both Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
    Fierce Biotech · 20h agoNegative readoutNegative↗ source
  • Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitals
    Several of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…
    STAT · 23h agoRegulatoryNegative↗ source
  • Alterome reports early Phase 1 data for KRAS-targeted therapy in pancreatic, lung and colon cancers
    Alterome has unveiled preliminary Phase 1 data for its experimental KRAS-targeted therapy. The drug is designed to hit a spectrum of KRAS mutations that drive several solid tumours. The early stud…
    STAT · 9h agoPositive readoutNeutral↗ source
  • UnitedHealth sues CMS over lowered 2027 Medicare Advantage star ratings
    UnitedHealth Group has filed a lawsuit against the Centers for Medicare & Medicaid Services seeking to overturn the agency’s lowered star ratings for its Medicare Advantage plans for 2027. The sui…
    STAT · 16h agoRegulatoryNegative↗ source
  • Medicare launches pilot to test nutrition and exercise programs as preventive care for chronic disease
    Department of Health and Human Services announced that fifteen groups across the United States will participate in a Medicare pilot aimed at evaluating lifestyle interventions for chronic disease p…
    STAT · 4h agoRegulatoryPositive↗ source
  • Scientists study blood markers for chronic traumatic encephalopathy using samples from 21 football players
    Researchers collected blood from 21 current football players and arranged for their brains to be donated after death to support chronic traumatic encephalopathy (CTE) research. The team is analyzi…
    STAT · 9h agoNeutral↗ source
  • Ailux appoints former Johnson & Johnson executive Lloyd Miller as chief medical officer
    Ailux announced the hiring of Lloyd Miller as its new chief medical officer. Miller comes from Johnson & Johnson where he served as senior vice president and global head of translational science &…
    STAT · 7h agoNeutral↗ source
  • Exercise should be prescribed alongside rest for concussion recovery, author argues
    The author recounts a severe brain injury that left him in a coma, caused significant muscle loss and left-side weakness, and made simple tasks like getting out of a bathtub a struggle. He began a…
    STAT · 14h agoPositive↗ source
  • Patient coalition urges more agency for participants in brain-implant trials
    A new report released by the BCI Pioneers Coalition outlines 13 recommendations aimed at improving how brain‑computer interface trials are conducted. The guidance targets startups, researchers and…
    STAT · 14h agoNeutral↗ source
  • Princeton graduate student detained by ICE after neuroscience conference, sparking fear among international researchers
    A Princeton University graduate student who conducts scientific research was taken into custody by Immigration and Customs Enforcement after returning from the Society for Neuroscience meeting in W…
    STAT · 2h agoNegative↗ source
  • MAHA Institute’s 2025 tax filing reveals cash reserves fell to $171,000 after spending over $1 million
    The MAHA Institute, a nonprofit created to support Robert F. Kennedy Jr.’s health agenda, reported in its 2025 IRS filing that it began the year with nearly $1.3 million in cash and ended with just…
    STAT · 3h agoNegative↗ source
  • Only 10% of surgeons in East and Central Africa are women, highlighting gender gap in global surgery
    An opinion piece notes that women comprise just one‑tenth of the surgical workforce across twelve COSECSA member countries, a proportion that has not changed in years. The author observed a documen…
    STAT · 14h agoNegative↗ source
  • ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loom
    As the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.
    Fierce Biotech · 16h agoNeutral↗ source